Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators.

Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.

PMID:
31679945
2.

A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma.

Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot G.

Cell Transplant. 2019 Oct 16:963689719880541. doi: 10.1177/0963689719880541. [Epub ahead of print]

PMID:
31619057
3.

Aerobic exercise during chemotherapy infusion for cancer treatment: a novel randomised crossover safety and feasibility trial.

Thomas VJ, Seet-Lee C, Marthick M, Cheema BS, Boyer M, Edwards KM.

Support Care Cancer. 2019 May 21. doi: 10.1007/s00520-019-04871-5. [Epub ahead of print]

PMID:
31115667
4.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N.

Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.

5.

Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer.

Prasanna T, Arasaratnam M, Boyer M, McNeil C, Barnet MB, Asher R, Hui R, Nagrial A, Kao S.

Immunotherapy. 2019 Jun;11(8):657-665. doi: 10.2217/imt-2018-0180.

PMID:
31088240
6.

Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019.

Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Cassaday RD, Litzow M, Advani A, Aoun P, Bhatnagar B, Boyer MW, Bryan T, Burke PW, Coccia PF, Coutre SE, Jain N, Kirby S, Liu A, Massaro S, Mattison RJ, Oluwole O, Papadantonakis N, Park J, Rubnitz JE, Uy GL, Gregory KM, Ogba N, Shah B.

J Natl Compr Canc Netw. 2019 May 1;17(5):414-423. doi: 10.6004/jnccn.2019.0024.

PMID:
31085755
7.

Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells.

Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, Tomassian L, Shah S, Leung M, Huang PH, Awasthi R, Mueller KT, Wood PA, June CH.

CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):285-295. doi: 10.1002/psp4.12388. Epub 2019 Mar 7.

8.

Processed human amniotic fluid retains its antibacterial activity.

Mao Y, Pierce J, Singh-Varma A, Boyer M, Kohn J, Reems JA.

J Transl Med. 2019 Mar 1;17(1):68. doi: 10.1186/s12967-019-1812-8.

9.

Extraterrestrial prebiotic molecules: photochemistry vs. radiation chemistry of interstellar ices.

Arumainayagam CR, Garrod RT, Boyer MC, Hay AK, Bao ST, Campbell JS, Wang J, Nowak CM, Arumainayagam MR, Hodge PJ.

Chem Soc Rev. 2019 Apr 15;48(8):2293-2314. doi: 10.1039/c7cs00443e. Review.

PMID:
30815642
10.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1569-1579. doi: 10.1007/s00432-019-02862-x. Epub 2019 Feb 19.

11.

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.

Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenkov Y, Ohe Y.

Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.

PMID:
30659024
12.

A cytoskeletal anchor connects ischemic mitochondrial fission to myocardial senescence.

Boyer MJ, Eguchi S.

Sci Signal. 2018 Nov 13;11(556). pii: eaav3267. doi: 10.1126/scisignal.aav3267. Review.

PMID:
30425163
13.

Mice deficient in the mitochondrial branched-chain aminotransferase (BCATm) respond with delayed tumour growth to a challenge with EL-4 lymphoma.

Ananieva EA, Bostic JN, Torres AA, Glanz HR, McNitt SM, Brenner MK, Boyer MP, Addington AK, Hutson SM.

Br J Cancer. 2018 Oct;119(8):1009-1017. doi: 10.1038/s41416-018-0283-7. Epub 2018 Oct 15.

14.

Novel role for cardiac myocyte-derived β-2 microglobulin in mediating cardiac fibrosis.

Boyer MJ, Eguchi S.

Clin Sci (Lond). 2018 Oct 5;132(19):2117-2120. doi: 10.1042/CS20180681. Print 2018 Oct 15.

PMID:
30291210
15.

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, Winckler W.

Nat Med. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1.

PMID:
30275569
16.

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.

Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah SS, Leung M, Taran T, Wood PA, Maude SL.

Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. doi: 10.1158/1078-0432.CCR-18-0758. Epub 2018 Sep 6.

PMID:
30190371
17.

Chimeric antigen receptor T-cell therapy hits the market.

Boyer MW.

Immunotherapy. 2018 Aug;10(11):911-912. doi: 10.2217/imt-2018-0075. No abstract available.

18.

Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists.

Bui KT, Cooper WA, Kao S, Boyer M.

J Clin Med. 2018 Jul 31;7(8). pii: E192. doi: 10.3390/jcm7080192. Review.

19.

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.

Gooptu M, Kim HT, Chen YB, Rybka W, Artz A, Boyer M, Johnston L, McGuirk J, Shea TC, Jagasia M, Shaughnessy PJ, Reynolds CG, Fields M, Alyea EP, Ho VT, Glavin F, Dipersio JF, Westervelt P, Ritz J, Soiffer RJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2216-2223. doi: 10.1016/j.bbmt.2018.07.002. Epub 2018 Jul 10.

20.

Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.

Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, Meshinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JM, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2040-2046. doi: 10.1016/j.bbmt.2018.06.010. Epub 2018 Jun 19.

Supplemental Content

Loading ...
Support Center